在抗癌治疗中选择泛HDAC或选择性HDAC抑制剂
Shabir Ahmad Ganai1, Mahreen Bhat1, Shahid Ahmad Padder1
1Division of Basic Sciences & Humanities, FoH, SKUAST-Kashmir, Shalimar, Srinagar, Jammu & Kashmir 190025, India.
Drug discovery today
|November 15, 2025
概括
基斯脱乙酶 (HDAC) 功能障碍驱动癌症. 将HDAC抑制剂 (HDACi) 定制为特定癌症的HDAC过度表达模式,可以优化治疗选择,以获得更好的治疗结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 海斯脱乙酶 (HDAC) 功能障碍与癌症的发展和进展有关.
- 在各种癌症类型中观察到经典HDACs的异常表达.
- 涉及的特定HDAC可以从单个过度活跃的异酶到多个类别.
研究的目的:
- 解决癌症治疗选择性和泛HDAC抑制剂之间最佳选择的模糊问题.
- 为选择最有效的HDAC抑制剂疗法提供基于证据的指导.
主要方法:
- 在不同类型的癌症中分析HDAC表达模式.
- 关于HDAC抑制剂 (HDACi) 及其疗效的现有文献的审查.
- HDAC过度表达特征与对HDACi的治疗反应的相关性.
主要成果:
- 在不同癌症中,HDAC表达模式是异质的.
- HDACs的参与可能是特定于某些异酶的,或包括多个类.
- 在特定的HDAC过度表达模式和特定的HDAC抑制剂的有效性之间存在明显的联系.
结论:
- 对HDAC抑制剂的最佳治疗策略取决于特定癌症的HDAC过度表达特征.
- 将HDAC抑制剂类型 (选择性与泛抑制剂) 与癌症的分子特征相匹配,对于有效治疗至关重要.
- 这种方法为基于HDAC抑制剂的癌症治疗提供了个性化的药物策略.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
421
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
421
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


